Patent classifications
C07C235/84
Heterocyclic P2Y.SUB.14 .receptor antagonists
Disclosed are compounds of formulas (I)-(IX) for treating or preventing a disease or disorder responsive to antagonism of a P2Y.sub.14R receptor agonist in a mammal in need thereof, wherein R.sup.1-R.sup.8, X, Y, Z, X′, Y′, Z′, and A are as defined herein, that are useful in treating an inflammatory such as asthma, cystic fibrosis, and sterile inflammation of the kidney. ##STR00001##
Material for forming organic film, substrate for manufacturing semiconductor device, method for forming organic film, patterning process, and compound for forming organic film
An object of the present invention is to provide: a compound containing an imide group which is not only cured under film formation conditions of inert gas as well as air and has excellent heat resistance and properties of filling and planarizing a pattern formed on a substrate, but can also form an organic underlayer film with favorable adhesion to a substrate, and a material for forming an organic film containing the compound. A material for forming an organic film, including: (A) a compound for forming an organic film shown by the following general formula (1A); and (B) an organic solvent, ##STR00001## noting that in the general formula (1B), when W.sub.1 represents ##STR00002## R.sub.1 does not represent any of ##STR00003##
Material for forming organic film, substrate for manufacturing semiconductor device, method for forming organic film, patterning process, and compound for forming organic film
An object of the present invention is to provide: a compound containing an imide group which is not only cured under film formation conditions of inert gas as well as air and has excellent heat resistance and properties of filling and planarizing a pattern formed on a substrate, but can also form an organic underlayer film with favorable adhesion to a substrate, and a material for forming an organic film containing the compound. A material for forming an organic film, including: (A) a compound for forming an organic film shown by the following general formula (1A); and (B) an organic solvent, ##STR00001## noting that in the general formula (1B), when W.sub.1 represents ##STR00002## R.sub.1 does not represent any of ##STR00003##
Small molecule inhibitors selective for polo-like kinase proteins
Disclosed are small molecule PLK inhibitors that can target the polo box domain (PBD). Inhibitors can have an atomic mass of about 1000 Da or less and a general structure of ##STR00001##
For instance, the inhibitors can include an alkyl benzamido benzoic acid core structure.
Small molecule inhibitors selective for polo-like kinase proteins
Disclosed are small molecule PLK inhibitors that can target the polo box domain (PBD). Inhibitors can have an atomic mass of about 1000 Da or less and a general structure of ##STR00001##
For instance, the inhibitors can include an alkyl benzamido benzoic acid core structure.
RHEIN AMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF, AND INHIBITOR OF HEPATOCELLULAR CARCINOMA (HCC) WITH SPECIFIC RECQL4 EXPRESSION
A rhein amide derivative and a preparation method and use thereof, and a drug for treating hepatocellular carcinoma (HCC) caused by a specific expression of RECQL4. The rhein amide derivative has a structure shown in any one of formulas I to IV. The rhein amide derivative has a relatively strong inhibitory effect on proliferation of HCC cells SNU-398 with RECQL4 high expression. Development of a novel anti-cancer drug for RECQL4 high expression-caused HCC and clinical personalized treatment of the RECQL4 high expression-caused HCC.
Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
Disclosed are small molecule PLK inhibitors that can target the polo box domain (PBD). Inhibitors can have an atomic mass of about 1000 Da or less and a general structure of
##STR00001##
For instance, the inhibitors can include an alkyl benzamido benzoic acid core structure.
Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
Disclosed are small molecule PLK inhibitors that can target the polo box domain (PBD). Inhibitors can have an atomic mass of about 1000 Da or less and a general structure of
##STR00001##
For instance, the inhibitors can include an alkyl benzamido benzoic acid core structure.